NRICM101 ameliorates SARS-CoV-2–S1-induced pulmonary injury in K18-hACE2 mice model
The coronavirus disease 2019 (COVID-19) pandemic continues to represent a challenge for public health globally since transmission of different variants of the virus does not seem to be effectively affected by the current treatments and vaccines. During COVID-19 the outbreak in Taiwan, the patients w...
Main Authors: | Wen-Chi Wei, Keng-Chang Tsai, Chia-Ching Liaw, Chun-Tang Chiou, Yu-Hwei Tseng, Geng-You Liao, Yu-Chi Lin, Wen-Fei Chiou, Kuo-Tong Liou, I-Shing Yu, Yuh-Chiang Shen, Yi-Chang Su |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-06-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1125414/full |
Similar Items
-
Pharmacological Mechanism of NRICM101 for COVID-19 Treatments by Combined Network Pharmacology and Pharmacodynamics
by: Sher Singh, et al.
Published: (2022-12-01) -
The development and application of NRICM101 and NRICM102 for the treatment of COVID-19
by: Shung-Tai Ho, et al.
Published: (2023-07-01) -
Efficacy analysis and research progress of complementary and alternative medicines in the adjuvant treatment of COVID-19
by: Jaung-Geng Lin, et al.
Published: (2023-05-01) -
<i>ACE2</i> and a Traditional Chinese Medicine Formula NRICM101 Could Alleviate the Inflammation and Pathogenic Process of Acute Lung Injury
by: Cheng-Han Lin, et al.
Published: (2023-08-01) -
The CMAR and extent of compliance with IFRS 101 standard among Malaysian ace market companies
by: Nor Asma Lode
Published: (2012-12-01)